| Dec-2025 | Sep-2025 | Jun-2025 | Mar-2025 | Dec-2024 | |
|---|---|---|---|---|---|
Promoter | - | - | - | - | - |
Foreign | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% |
Indian | 0% | 0% | 0% | 0% | 0% |
Total Promoter | - | - | - | - | - |
Institutions | 40.56% | 40.54% | 40.23% | 40.17% | 39.83% |
Non-Institutions | 7.6% | 7.62% | 7.92% | 7.99% | 8.33% |
Total Non-Promoter | 48.16% | 48.16% | 48.16% | 48.16% | 48.16% |
Custodian | 0% | 0% | 0% | 0% | 0% |
Total | 100% | 100% | 100% | 100% | 100% |
The European business reported a 54 percent year on year surge in topline during the quarter.
Here are some of the stocks that may see significant price movement today: Infosys, Tata Steel, Cipla Limited, etc.
Here are some of the stocks that may see significant price movement: Bharti Airtel, Cipla, Gland Pharma, etc.
Here are some of the stocks that may see significant price movement today: Avenue Supermarts, BEML, Gland Pharma, etc.
The receipt of the EIR marks the formal closure of the US health regulator’s pre-approval inspection, which was conducted between February 19 and February 25, 2025.
Here are some of the stocks that may see significant price movement today: Hindustan Aeronautics, Gland Pharma, REC, etc.
Gland Pharma also established that its version is bioequivalent and therapeutically equivalent to the reference listed drug.
Gland Pharma net profit was at ₹186.5 crore as against ₹192.4 crore in the year-ago quarter of FY24.
Gland Pharma has secured exclusive rights as the first-to-file sponsor of this generic product. This makes it eligible for 180 days of marketing exclusivity in the US
The FDA conducted the pre-approval inspection (PAI) from Feb. 19, 2025, to Feb. 25, 2025, as part of the regulatory process for sterile APIs.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
